Search alternatives:
significantly impact » significant impact (Expand Search), significantly improve (Expand Search), significantly improved (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
significantly impact » significant impact (Expand Search), significantly improve (Expand Search), significantly improved (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
-
161
Comparison of adhesiveness ranges for different food categories under IDDSI levels.
Published 2025Subjects: -
162
-
163
-
164
-
165
-
166
Statistical analysis of adhesiveness, hardness, and cohesiveness across IDDSI levels.
Published 2025Subjects: -
167
Comparison of hardness ranges for different food categories under IDDSI levels.
Published 2025Subjects: -
168
-
169
-
170
-
171
Activity of female and male <i>M. marinus</i> (left column) and <i>G. pulex</i> (right column).
Published 2025Subjects: -
172
-
173
-
174
-
175
-
176
-
177
-
178
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
179
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
180
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”